Cytek Biosciences (CTKB) Stock Analysis & AI Equity Report

Medical - Devices USD Explore free reports

Cytek Biosciences (CTKB) overview

Cytek Biosciences (CTKB) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 201m and operating profit of USD -40.4m; the year-end share price was 5.05 USD and market capitalisation was USD 649m. Cytek Biosciences is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Cytek Biosciences's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 342mFY 2025
Share price5.05 USDFY 2025 year end
RevenueUSD 201mFY 2025
Operating profitUSD -40.4mFY 2025
Net earningsUSD -66.5mFY 2025
Market capitalisationUSD 649mFY 2025 year end

About Cytek Biosciences

Cytek develops cell analysis systems using its Full Spectrum Profiling technology, which analyzes light emissions from multiple lasers to distinguish fluorescent tags on single cells. Its products include cell analyzers, a cell sorter, embedded software, reagents, and service offerings. Customers include pharmaceutical and biopharmaceutical companies, academic research centers, and contract research organizations.

Generate the Cytek Biosciences report

Cytek Biosciences is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Cytek Biosciences and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Cytek Biosciences

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.